Summary
Boston Scientific Corporation (BSX) has announced a change to its Board of Directors through a Form 8-K filing. Effective June 23, 2021, the Board has been expanded from nine to ten members with the appointment of David S. Wichmann. Mr. Wichmann will serve as a director until the next annual stockholders meeting. His appointment is part of a broader strategy to enhance board expertise and oversight. Mr. Wichmann's compensation as a non-employee director will be prorated from his appointment date until the 2022 annual meeting. This includes a cash retainer of approximately $99,500 and an equity award valued at approximately $177,400. The company has also stated its intention to enter into an indemnification agreement with Mr. Wichmann, consistent with existing agreements for other directors. The press release announcing this appointment was issued on June 24, 2021.
Key Highlights
- 1Board expansion from nine to ten directors.
- 2Appointment of David S. Wichmann as a new director, effective June 23, 2021.
- 3Mr. Wichmann to serve as a director until the next annual meeting of stockholders.
- 4Prorated director compensation for Mr. Wichmann: approximately $99,500 cash retainer and $177,400 in equity award.
- 5Standard director indemnification agreement to be entered into with Mr. Wichmann.
- 6No undisclosed arrangements or material interests in transactions for Mr. Wichmann's appointment.